About Novartis
Novartis is a company based in Stevenage (United Kingdom) founded in 2016 was acquired by Novartis in December 2021. It operates as a Direct-to-Consumer (D2C) and Professional Services. Novartis has raised $255.04 million across 5 funding rounds from investors including Novartis, T. Rowe Price and Sanofi. Novartis has completed 1 acquisition, including Orbit Biomedical. Novartis offers products and services including Zolgensma and Cosentyx. Novartis operates in a competitive market with competitors including Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.
- Headquarter Stevenage, United Kingdom
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Novartis Ag
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$255.04 M (USD)
in 5 rounds
-
Latest Funding Round
$40 M (USD), Series C
Nov 08, 2021
-
Investors
Novartis
& 10 more
-
Employee Count
Not available
- Investments & Acquisitions
-
Acquired by
Novartis
(Dec 22, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Novartis
Novartis offers a comprehensive portfolio of products and services, including Zolgensma and Cosentyx.
Gene therapy for spinal muscular atrophy is provided.
Treatment for autoimmune diseases is offered by Novartis.
People of Novartis
Unlock access to complete
Unlock access to complete
Scientific Team
9 people
Clinical Team
7 people
Leadership Team
7 people
Product Management Team
6 people
Software Development Team
4 people
Board Team
3 people
Operations Team
2 people
Human Resources and Administration
2 people
Unlock access to complete
Funding Insights of Novartis
Novartis has successfully raised a total of $255.04M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $40 million completed in November 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Novartis
Novartis has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Novartis, T. Rowe Price and Sanofi.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are made in life sciences and deep tech.
|
Locked | Locked | Locked | |
|
Biotech funding, drug development support, and investment in life sciences.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on lifescience and healthcare sectors
|
Locked | Locked | Locked |
Investor details for Novartis
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Novartis
Novartis has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Orbit Biomedical.
Investment portfolio details for Novartis
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Medical device for ophthalmic surgery is developed.
|
Locked | Locked | 2018 | Locked |
Complete acquisition details for Novartis
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Novartis
Detailed financials for Novartis
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Novartis Comparisons
Peer comparison for Novartis
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Novartis
Novartis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases are developed to treat patients.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Provider of cell therapies to treat cancer and hematologic conditions
|
Detailed competitors of Novartis
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Novartis
Complete news archive for Novartis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Novartis
Novartis was founded in 2016.
Novartis is headquartered in Stevenage, United Kingdom. It is registered at Stevenage, Hertfordshire, United Kingdom.
Novartis is a funded company, having raised a total of $255.04M across 5 funding rounds to date.
Novartis is established as a global leader in innovative medicines, focusing on reimagining healthcare to improve and extend lives. The company operates in key therapeutic areas such as cardiovascular, renal, metabolic, immunology, neuroscience, and oncology. Solutions are developed to address significant disease burdens, reaching 296 million people worldwide. Research and development efforts are centered on breakthrough science, with a robust pipeline of transformative treatments. Novartis is committed to societal impact through access programs, environmental sustainability, and ethical standards.
Novartis's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Novartis offers Zolgensma and Cosentyx.
Novartis has made 1 acquisition, including Orbit Biomedical.
Novartis has 11 investors. Key investors include Novartis, T. Rowe Price, Sanofi, Syncona, and Fosun Pharmaceutical.